Vivanza Biosciences Ltd

Vivanza Biosciences Ltd. announces that Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning the disclosure of related party transactions, will not be applicable for the quarter and year ending March 31, 2026. As of March 31, 2025, the company's paid-up equity share capital is ₹4,00,00,000 and its net worth is ₹4,02,03,752.40, which falls below the threshold of ₹10 Crores and ₹25 Crores respectively, as per Regulation 15(2) of SEBI (LODR) Regulations, 2015.

Vivanza Biosciences Ltd. announced audited standalone financial results for the quarter and year ended March 31, 2026. The board approved the results and noted the resignations of Hemant A. Parikh as a Non-Executive Director (effective March 17, 2026) and Chaitra Arora as Company Secretary & Compliance Officer (effective April 30, 2026). The board also approved the reconstitution of various committees, including the Audit Committee and Nomination & Remuneration Committee, effective May 7, 2026.

Vivanza Biosciences Ltd's Board of Directors approved the audited standalone and consolidated financial results as per Indian Accounting Standards (Ind AS) for the quarter and year ended March 31, 2026. The board also took note of the resignations of Mr. Hemant Amrish Parikh as a Non-Executive Director (effective March 17, 2026) and CS Chaitra Arora as Company Secretary & Compliance Officer (effective April 30, 2026). Additionally, the Board approved the reconstitution of various committees, including the Audit Committee.

Vivanza Biosciences Ltd has rescheduled its Board of Directors meeting to May 7, 2026, from the previously scheduled date of May 4, 2026, due to unavoidable circumstances. The meeting will consider and approve the audited standalone and consolidated financial results along with the Audit Report of the Company for the quarter and year ended March 31, 2026. The trading window, previously intimated, will remain closed until 48 hours after the declaration of the results.

Vivanza Biosciences Ltd has announced that its Board of Directors will convene on Monday, May 4, 2026. The primary agenda for the meeting is to consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and fiscal year ended March 31, 2026. Additionally, the trading window for dealing in the company's securities remains closed for designated persons until 48 hours after the declaration of these financial results, in compliance with SEBI Insider Trading Regulations.

Vivanza Biosciences Ltd has confirmed the non-applicability of the Statement of Deviation or Variation from proceeds of public/rights/preferential issues, as per Regulation 32 of SEBI (LODR) Regulations, 2015, read with SEBI Circular dated December 24, 2019. The company stated that it has not raised any further funds through Public Issue, Rights Issue, or Preferential Issue, etc., making the submission of such a statement unnecessary.

In accordance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, two promoters of Vivanza Biosciences Ltd have declared their shareholdings and encumbrance status as of March 31, 2026. One promoter held 1,00,211 shares, while the other held 79,07,622 shares. Neither promoter had made any encumbrance of shares, directly or indirectly, during the Financial Year ended March 31, 2026. This disclosure is a part of the yearly disclosure requirement under the aforementioned regulation.

Vivanza Biosciences Ltd has announced the resignation of Mr. Hemant Amrish Parikh as a Non-Executive Director of the company with effect from March 17th, 2026 due to personal reasons. Mr. Parikh confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter.

Vivanza Biosciences Ltd has announced the resignation of Mr. Hemant Amrish Parikh as a Non-Executive Director of the company, effective from the close of business hours on March 17th, 2026. The resignation is due to personal reasons, and Mr. Parikh has confirmed that there are no material reasons for his resignation beyond those mentioned in his resignation letter.

Vivanza Biosciences Ltd. has confirmed, pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that it has not raised any further funds by means of Public Issue, Rights Issue, or Preferential Issue, etc. The company also stated that it does not need to provide a Statement of deviation(s) or variation(s) as it is not applicable.